To investigate the mechanisms that led to the observed differential effect between the two MS phenotypes, we used single-cell RNA sequencing (scRNA-Seq) to identify specific changes in the transcriptome upon treatment with TNF-α/IL-17A. This evidence concerns the gene TNF and myeloid sarcoma.